Prestige Biologics achieves ISO certifications, enhancing its global position as a leading ESG CDMO company

Prestige Biologics, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), is pleased to announce its recent acquisition of international certifications from the International Organization for Standardization (ISO).

The company has successfully obtained 'ISO 45001' (Occupational Health and Safety Management System) and 'ISO 14001' (Environmental Management System), coupled with the renewal of 'ISO 9001' (Quality Management System), enhancing its position as a global ESG-focused CDMO.

These certifications highlight Prestige Biologics' commitment to international standards and sustainable practices. ISO 14001 recognizes the company's efforts to minimize environmental impact through sustainable practices. ISO 45001 reflects Prestige Biologics' systematic approach to ensuring occupational health and safety in the workplace. ISO 9001 demonstrates Prestige Biologics' dedication to maintaining strict quality management standards.

With a focus on ESG (Environmental, Social, Governance) management, Prestige Biologics aligns its vision of ‘Innovation for Life’ with a commitment to quality, safety, and responsible business practices.

“We take great pride in achieving these internationally recognized ISO certifications,” said Duk Hoon Hyun, the CEO of Prestige Biologics. “These certifications emphasize our strong commitment to maintaining the highest global standards, evidencing our dedication to building and preserving client trust and satisfaction.”

About Prestige Biologics:

Prestige Biologics is a leading biopharmaceutical Contract Development, Engineering, and Manufacturing Organization (CDMO) with advanced production facilities located in South Korea. With a manufacturing capacity of 154,000 liters, Prestige Biologics ranks among the top 10 global CDMO companies, specializing in animal cell culture technologies.